Matrigel Tube-Formation Assay for Quantifying Pro- and Anti-Angiogenic Modulation of Human Umbilical Vein Endothelial Cells (HUVECs)

Each condition is run in technical triplicate wells per plate and repeated in ≥3 independent experiments using HUVECs from ≥2 donor lots (or pooled HUVECs) at passage 3-6. Concentration series: VEGF (0, 10, 25, 50 ng/mL), suramin (10-100 µM), bevacizumab (1-100 µg/mL, with and without VEGF). Imaging at a fixed time point (commonly 6 h; optionally a time course at 4, 6, 8, 18 h). Well positions are randomized; image analysis is performed blinded to condition. A parallel viability assay (e.g., MTT/CTG) controls for cytotoxicity confounds.

BSL-2 for primary human endothelial cells; all open work in a biosafety cabinet. Matrigel is a murine EHS-sarcoma-derived basement-membrane extract — handle as biohazardous and keep cold to prevent premature gelling. Suramin is a hazardous compound (avoid inhalation/skin contact); bevacizumab is a therapeutic antibody handled with standard biologics precautions. Calcein-AM is in DMSO. PPE: lab coat, nitrile gloves, safety glasses. Liquid waste is bleached (10% final); plasticware autoclaved or chemically decontaminated. Trypsin and FBS handled per standard tissue-culture practice.

Positive control: VEGF (25-50 ng/mL) must enhance network formation over basal medium. Negative/basal control: basal EBM-2 + low FBS without stimulation defines baseline network. Anti-angiogenic positive control: suramin must reduce networks. Antibody specificity controls: bevacizumab + VEGF should block the VEGF increment, while a matched human IgG isotype control + VEGF should NOT block it (confirms VEGF-specific inhibition). Vehicle control: water/PBS carrier matched in volume. Viability control: a parallel cytotoxicity assay distinguishes true anti-angiogenesis from cell death.

Within 4-8 h, HUVECs in basal medium form a moderate capillary-like lattice. VEGF-stimulated wells show denser networks with ~20-60% more total tube length and more branch points and meshes. Suramin and VEGF-neutralizing bevacizumab reduce network metrics dose-dependently, often to sparse cords or isolated cells at high doses, while isotype IgG does not. Typical readouts: branch points increasing from ~30-60/field (basal) to higher with VEGF, and meshes collapsing under inhibition. Networks regress (over-mature) by 18-24 h, so the analysis window is critical.

• HUVECs (pooled or single-donor), passage 3-6, in EGM-2 (endothelial growth medium-2, with bullet-kit supplements)
• Growth-factor-reduced Matrigel (Corning 354230), thawed on ice overnight, kept cold
• Basal assay medium: EBM-2 + 0.5-2% FBS (low-growth-factor, to reveal stimulation)
• Recombinant human VEGF-A165 (e.g., PeproTech 100-20), working 10-50 ng/mL
• Suramin sodium, 50 mM stock in water; working 10-100 µM
• Bevacizumab (anti-VEGF mAb), working 1-100 µg/mL
• Human IgG isotype control (matched to bevacizumab)
• Calcein-AM (2 µM) for live network visualization (optional)
• Pre-chilled pipette tips and 96-well or 15-well µ-Slide angiogenesis plates

To establish a reproducible in vitro angiogenesis (tube-formation) assay in which HUVECs seeded on growth-factor-reduced Matrigel self-organize into capillary-like networks within 4-18 h, and to quantify network architecture (total tube length, number of branch points/nodes, number of closed meshes, total mesh area) under defined pro- and anti-angiogenic conditions.

1. Day before: thaw GFR-Matrigel on ice overnight; pre-chill plates, tips, and pipettes at 4°C.
2. Coat wells with cold Matrigel (e.g., 50 µL/well in a 96-well plate or 10 µL in a µ-Slide) avoiding bubbles; gel at 37°C for 30-60 min.
3. Harvest HUVECs with trypsin/EDTA, neutralize, count, and resuspend in basal assay medium containing the test treatment (VEGF, suramin, bevacizumab ± VEGF, or vehicle).
4. Seed ~1-2 x10^4 HUVECs/well (96-well) onto the polymerized Matrigel in 100 µL.
5. Incubate at 37°C / 5% CO2; do not disturb.
6. At the fixed time point (e.g., 6 h), image each well by phase contrast (or load 2 µM calcein-AM for 15 min and image fluorescence) at 4x covering the well center.
7. Optionally fix/stain or run a parallel viability assay on sister wells.
8. Acquire a consistent number of fields per well at identical magnification/exposure for quantification.

Independent variables: treatment identity and concentration (VEGF, suramin, bevacizumab, isotype), and time point. Dependent variables: total tube/segment length, number of branch points (nodes), number of meshes (closed loops), total mesh area, and mean tube thickness. Controlled variables: Matrigel lot and coating volume/time, HUVEC passage (3-6) and seeding density, assay medium FBS%, incubation time/temperature, imaging magnification/exposure, and number of fields per well. Cell viability is measured to control for cytotoxic confounding.

VEGF-A165 stimulation will increase network complexity (greater total tube length, more branch points and meshes) relative to basal medium, whereas anti-angiogenic agents — suramin (broad growth-factor antagonist) and the anti-VEGF antibody bevacizumab — will reduce network formation in a concentration-dependent manner, with bevacizumab specifically blocking the VEGF-driven increment. We predict tube-formation metrics will track angiogenic stimulus more sensitively than simple cell viability.

Images are quantified with the ImageJ 'Angiogenesis Analyzer' plugin (or WimTube/AngioTool), which segments the network and reports total segment/tube length, number of nodes/branch points, number of meshes, and total mesh area per field. Values are averaged across fields per well and normalized to the basal control (set to 100%) within each independent experiment to allow cross-experiment pooling. Identical thresholding parameters are applied to all images in a batch, and analysis is performed blinded to treatment.

1. No tubes / cells stay rounded or clumped: Matrigel too thin/uneven or warmed prematurely — keep everything cold, avoid bubbles, and use sufficient gel volume; verify GFR-Matrigel protein concentration. 2. Networks form everywhere with no treatment difference: assay medium too rich (full EGM-2 supplements) — switch to basal EBM-2 + low FBS to create a stimulatable window. 3. Networks already regressed at imaging: time point too late — image at 4-6 h and run a time course to find the optimum for your lot. 4. High well-to-well variability: uneven seeding/coating — pre-chill tips, mix cell suspension well, and standardize coating volume and gelling time. 5. Apparent inhibition is actually toxicity: run the parallel viability assay; if viability drops, attribute the effect to cytotoxicity, not anti-angiogenesis.

Normalized metrics are compared across treatments by one-way ANOVA (or two-way for VEGF × inhibitor designs) with Tukey's or Dunnett's post-hoc correction (α=0.05), using independent experiments (n≥3) as the experimental unit (technical-replicate wells averaged first to avoid pseudoreplication). The bevacizumab-vs-isotype contrast tests VEGF specificity. Power analysis for detecting a 25% change in total tube length (SD≈12%) at 80% power, α=0.05 gives n≈4 independent experiments. Non-normal metrics use Kruskal-Wallis with Dunn's correction.